Month: November 2021

Abivax’s Phase 1/2 Clinical Study Results of ABX196 in Liver Cancer Show Good Tolerability and Promising Signals of Clinical Benefit and were Selected for Presentation at the ASCO GI Cancers Symposium 2022

ABX196 is Abivax's second compound in clinical development after lead drug-candidate ABX464ABX196 was well tolerated and demonstrated promising signals of...

NLS Pharmaceutics Announces Preclinical Results Confirming the Potential Benefit and Safety Profile of NLS-4 for Circadian Rhythm Dysregulation and Chronic Fatigue Syndrome in Long-Covid Model

Emergex confirms its next generation T-Cell Priming COVID-19 vaccine candidate has the potential to be effective against all currently sequenced viral mutations

PRESS RELEASE Emergex confirms its next generation T-Cell Priming COVID-19 vaccine candidate has the potential to be effective against all...

error: Content is protected !!